Skip to main content
Caplight Logo









Antiva Biosciences

Antiva Biosciences

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://antivabio.com/

Last Round

Series E

Apr 27, 2023

Total Funding Raised

$141.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Antiva Biosciences is a biotechnology company that develops small molecule antivirals aimed at enhancing health outcomes for patients affected by HPV and other viral infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalhuman papillomavirusHPVtopical antiviralcervical cancer preventionclinical trialsbiotechdrug developmenthigh-risk HPVhrHPVcervical healththerapeutic candidateclinical-stage biotechprecancerous lesionsdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Antiva Biosciences Comparables

Compare Antiva Biosciences with similar companies based on industry and business-model similarity.

Antiva Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Frantz Viral Therapeutics
82%
Amplexd Therapeutics
76%
Asieris Pharmaceuticals
73%

Antiva Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series EApr 27, 2023
Series DNov 2, 2021
Series C ExtensionJul 10, 2018
Series CMar 28, 2017
Series BAug 6, 2015
Series A
Jul 1, 2014

Key People

Founding team and executive leadership

Kristine Ball

Chief Executive Officer

Executive Team

Antiva Biosciences Investors

Notable investors and investment history

Antiva Biosciences investors
InvestorRounds
Sirona CapitalSeries C Extension, Series D
Brace Pharma CapitalSeries C, Series C Extension, Series D
GVSeries E, Series D
Hillhouse InvestmentSeries C Extension
GaingelsSeries D
Mana VenturesSeries D
Avestria VenturesSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 70% MoM.

  • May 15, 2026

    Monthly visitors grew 530% MoM, reaching 1.8K.

Antiva Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Antiva Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Antiva Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedwood City, California
Employee Range19
Year Founded2012
Last FundingApr 27, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?